Literature DB >> 20506186

Positron emission tomography imaging of dopamine D₂/₃ receptors in the human cortex with [¹¹C]FLB 457: reproducibility studies.

Rajesh Narendran1, N Scott Mason, Maureen A May, Chi-Min Chen, Steve Kendro, Khanum Ridler, Eugenii A Rabiner, Marc Laruelle, Chester A Mathis, W Gordon Frankle.   

Abstract

In a recent PET study, we demonstrated the ability to measure amphetamine-induced DA release in the human cortex with the relatively high affinity dopamine D₂/₃ radioligand [¹¹C]FLB 457 (Narendran et al., [2009] Synapse 63:447-461). The aim of this study was to evaluate the reproducibility and reliability of [¹¹C]FLB 457 in the same imaging paradigm we used to measure amphetamine-induced DA transmission. Six healthy human subjects (three males/three females)were studied twice with [¹¹C]FLB 457, once at baseline and again 3 h following the end of the baseline scan. D₂/₃ receptor binding parameters were estimated using a two-tissue compartment kinetic analysis in the cortical regions of interest and cerebellum (reference region). The test-retest variability and intraclass correlation coefficient were assessed for distribution volume (VT), binding potential relative to plasma concentration (BP(P)), and binding potential relative to non-displaceable uptake (BP(ND)) of [¹¹C]FLB 457. The test-retest variability of [¹¹C]FLB 457 VT, BPP, and BP(ND) were ≤15%, consistent with the published test-retest variability for this ligand in other brain regions (Sudo et al., [2001] Nucl Med Commun 22:1215-1221; Vilkman et al., [2000] Eur J Nucl Med 27:1666-1673). In addition, no significant decrease in [¹¹C]FLB457 BP(ND) was observed in the second scan compared to the first one. This suggests that the contribution of carryover mass of [¹¹C]FLB 457 to the measured reduction in[¹¹C]FLB 457 BP(ND) following amphetamine was relatively low. These data support the further validation of [¹¹C]FLB 457 as a tool to measure amphetamine-induced dopamine release in the human cortex.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20506186      PMCID: PMC2939958          DOI: 10.1002/syn.20813

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  20 in total

1.  Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain.

Authors:  H Olsson; C Halldin; C G Swahn; L Farde
Journal:  J Cereb Blood Flow Metab       Date:  1999-10       Impact factor: 6.200

Review 2.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

3.  Optimal metabolite curve fitting for kinetic modeling of 11C-WAY-100635.

Authors:  Songmei Wu; R Todd Ogden; J John Mann; Ramin V Parsey
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

4.  HRRT versus HR+ human brain PET studies: an interscanner test-retest study.

Authors:  Floris H P van Velden; Reina W Kloet; Bart N M van Berckel; Fred L Buijs; Gert Luurtsema; Adriaan A Lammertsma; Ronald Boellaard
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

5.  Measurement of extrastriatal D2-like receptor binding with [11C]FLB 457--a test-retest analysis.

Authors:  H Vilkman; J Kajander; K Någren; V Oikonen; E Syvälahti; J Hietala
Journal:  Eur J Nucl Med       Date:  2000-11

6.  Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility.

Authors:  A Abi-Dargham; D Martinez; O Mawlawi; N Simpson; D R Hwang; M Slifstein; S Anjilvel; J Pidcock; N N Guo; I Lombardo; J J Mann; R Van Heertum; C Foged; C Halldin; M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2000-02       Impact factor: 6.200

7.  Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride.

Authors:  Rajesh Narendran; W Gordon Frankle; N Scott Mason; Eugenii A Rabiner; Roger N Gunn; Graham E Searle; Shivangi Vora; Maralee Litschge; Steve Kendro; Thomas B Cooper; Chester A Mathis; Marc Laruelle
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

8.  Measurement of GABAA receptor binding in vivo with [11C]flumazenil: a test-retest study in healthy subjects.

Authors:  Elina Salmi; Sargo Aalto; Jussi Hirvonen; Jaakko W Långsjö; Anu T Maksimow; Vesa Oikonen; Liisa Metsähonkala; Jussi Virkkala; Kjell Någren; Harry Scheinin
Journal:  Neuroimage       Date:  2008-03-04       Impact factor: 6.556

9.  Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET.

Authors:  R N Gunn; P A Sargent; C J Bench; E A Rabiner; S Osman; V W Pike; S P Hume; P M Grasby; A A Lammertsma
Journal:  Neuroimage       Date:  1998-11       Impact factor: 6.556

10.  Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors.

Authors:  C Halldin; L Farde; T Högberg; N Mohell; H Hall; T Suhara; P Karlsson; Y Nakashima; C G Swahn
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

View more
  24 in total

1.  In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB.

Authors:  Christine DeLorenzo; Jean-Dominique Gallezot; John Gardus; Jie Yang; Beata Planeta; Nabeel Nabulsi; R Todd Ogden; David C Labaree; Yiyun H Huang; J John Mann; Fabrizio Gasparini; Xin Lin; Jonathan A Javitch; Ramin V Parsey; Richard E Carson; Irina Esterlis
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 2.  Pain, affective symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction.

Authors:  Johanna M Jarcho; Emeran A Mayer; Ziyue Karen Jiang; Natasha A Feier; Edythe D London
Journal:  Pain       Date:  2012-03-03       Impact factor: 6.961

3.  Imaging Cortical Dopamine Transmission in Cocaine Dependence: A [11C]FLB 457-Amphetamine Positron Emission Tomography Study.

Authors:  Rajesh Narendran; Neale Scott Mason; Michael L Himes; W Gordon Frankle
Journal:  Biol Psychiatry       Date:  2020-04-12       Impact factor: 13.382

4.  Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.

Authors:  Rajesh Narendran; N Scott Mason; Chi-Min Chen; Michael Himes; Patrick Keating; Maureen A May; Eugenii A Rabiner; Marc Laruelle; Chester A Mathis; W Gordon Frankle
Journal:  Synapse       Date:  2011-04-26       Impact factor: 2.562

5.  Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [11C]FLB 457 Positron Emission Tomography Study.

Authors:  Naren Rao; Georg Northoff; Abanti Tagore; Pablo Rusjan; Miran Kenk; Alan Wilson; Sylvain Houle; Antonio Strafella; Gary Remington; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

6.  Failure to detect amphetamine-induced dopamine release in the cortex with [11 C]FLB 457 positron emission tomography (PET): Methodological considerations.

Authors:  Joshua Gertler; Savannah Tollefson; Rehima Jordan; Michael L Himes; N Scott Mason; W Gordon Frankle; Rajesh Narendran
Journal:  Synapse       Date:  2018-07-13       Impact factor: 2.562

Review 7.  PET Neurochemical Imaging Modes.

Authors:  Michael S Placzek; Wenjun Zhao; Hsiao-Ying Wey; Thomas M Morin; Jacob M Hooker
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

8.  Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.

Authors:  Suwanna Vangveravong; Zhanbin Zhang; Michelle Taylor; Melissa Bearden; Jinbin Xu; Jinquan Cui; Wei Wang; Robert R Luedtke; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2011-04-16       Impact factor: 3.641

9.  Imaging cortical dopamine concentrations, at last! Application to the neurobiology of alcohol dependence.

Authors:  Gwenn S Smith
Journal:  Am J Psychiatry       Date:  2014-08       Impact factor: 18.112

10.  Decreased prefrontal cortical dopamine transmission in alcoholism.

Authors:  Rajesh Narendran; Neale Scott Mason; Jennifer Paris; Michael L Himes; Antoine B Douaihy; W Gordon Frankle
Journal:  Am J Psychiatry       Date:  2014-08       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.